Continuation and maintenance treatments in major depression: The neglected role of monoamine oxidase inhibitors

Journal of Psychiatry and Neuroscience

Volumn 22, Issue 2, 1997, Pages 127-131

  Kennedy, Sidney H ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

Author keywords

continuation therapy; long term treatment; maintenance; major depression; moclobemide; monoamine oxidase inhibitors

Indexed keywords

IMIPRAMINE; ISOCARBOXAZID; MOCLOBEMIDE; MONOAMINE OXIDASE INHIBITOR; NORTRIPTYLINE; PHENELZINE; TRANYLCYPROMINE;

CLINICAL TRIAL; DEPRESSION; DRUG EFFICACY; DRUG TOLERABILITY; HUMAN; LONG TERM CARE; REVIEW;

ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; LONG-TERM CARE; MONOAMINE OXIDASE INHIBITORS; PHENELZINE; TRANYLCYPROMINE; TREATMENT OUTCOME;

EID: 0031009436     PISSN: 11804882     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (34)

1. Amsterdam JD. 1991. Use of high dose tranylcypromine in resistant depression. In: Amsterdam JD, editor. Refractory depression. New York: Raven Press, p 123-30.
2. Berlanga C, Ortega-Soto HA. 1995. A 3-year follow-up of a group of treatment-resistant depressed patients with a MAOI/tricyclic combination. J Affect Disord 34:187-92.
3. Cohen BM, Baldessarini RJ. 1985. Tolerance to therapeutic effects of antidepressants. Am J Psychiatry 142:489-90.
4. Davidson J, Raft D. 1984. Use of phenelzine in continuation therapy. Neuropsychobiology 11:191-4.
5. Donaldson SR. 1989. Tolerance to phenelzine and subsequent refractory depression: three cases. J Clin Psychiatry 50:33-5.
6. Ferner IN, Eccleston D, Moore PB, Wood KA. 1990. Relapse in chronic depressives on withdrawal of 1-tryptophan. Lancet 336:380-1.
7. Fitton A, Faulds D, Goa KL. 1992. Moclobemide: a review of its pharmacological properties and therapeutic use in depressive illness. Drugs 43:561-96.
8. Gagiano CA, Muller FGM, de Kock RF, Schall R. 1995. Moclobemide in continuation treatment of major depressive episodes: an open follow-up study over six mo. J Clin Psychopharmacol 15(2 Suppl):46S-50S.
9. Georgotas A, McCue RE, Cooper TB. 1989. A placebo-controlled comparison of nortriptyline and phenelzine in maintenance therapy of elderly depressed patients. Arch Gen Psychiatry 46:783-6.
10. Guelfi J-D, Lancrenon S, Pedarriosse A-M, Amrein R, Stahl M. 1994. Recent clinical developments with reversible and selective amine oxidase inhibitors - long-term prophylactic effect of moclobemide in patients with recurrent major depression (DSM-III-R) [abstract]. Neuropsychopharmacology 10(3 Suppl):416S.
11. Hamilton M. 1960. A rating scale for depression. J Neurol Neurosurg Psychiatry 23:56-62.
12. Harrison W, Rabkin J, Stewart JW, McGrath PJ, Tricamo E, Quitkin F. 1986. Phenelzine for chronic depression: a study of continuation treatment. J Clin Psychiatry 47:346-9.
13. Himmelhoch JM, Thase ME, Mallinger AG, Houck P. 1991. Tranylcypromine versus imipramine in anergic bipolar depression. Am J Psychiatry 148:910-6.
14. Kennedy SH, Glue P. 1994. MAOIs: past, present and future. In: Kennedy SH, editor. Clinical advances in monoamine oxidase inhibitor therapies. Washington (DC): American Psychiatric Press; p 279-90.
15. Kupfer DJ. 1993. Management of recurrent depression. J Clin Psychiatry 54(2 Suppl):29S-33S.
16. Liebowitz MR, Quitkin FM, Stewart JW, McGrath PJ, Harrison WM, Markowitz JS, Rabkin JG, Tricamo E, Goetz DM, Klein DF. 1988. Antidepressant specificity in atypical depression. Arch Gen Psychiatry 45:129-37.
17. Lonnqvist J, Sihvo S, Syvalahti E, Sintonen H, Kiviruusu O, Pitkanen H. 1995. Moclobemide and fluoxetine in the prevention of relapses following acute treatment of depression. Acta Psychiatr Scand 91:189-94.
18. Medical Research Council. 1965. Clinical trial of the treatment of depressive illness. BMJ 1:881-6.
19. Moll E, Neumann N, Schmid-Burgk W, Stabl M, Amrein R. 1994. Safety and efficacy during long-term treatment with moclobemide. Clin Neuropharmacol 17 (1 Suppl): 74S-87S.
20. Moller H-J, Volz H-P. 1992. Brofaromine in major depressed patients: a controlled clinical trial versus imipramine and open follow-up of up to one year. J Affect Disord 26:163-72.
21. Montgomery SA, Henry J, McDonald G, Dinan T, Lader M, Hindmarch I, Clare A, Nutt D. 1994. Selective serotonin reuptake inhibitors: meta-analysis of discontinuation rates. Int Clin Psychopharmacol 9:47-53.
22. Nutt D, Glue P. 1989. Monoamine oxidase inhibitors: rehabilitation from recent research. Br J Psychiatry 154:287-91.
23. Pare CMB. 1985. The present status of monoamine oxidase inhibitors. Br J Psychiatry 146:576-84.
24. Persad E, Oluboka OJ. 1995. The loss of the therapeutic effect of antidepressant medication [letter]. Can J Psychiatry 40:361-2.
25. Quitkin FM, McGrath PJ, Stewart JW, Harrison W, Wager SG, Nunes E, Rabkin JG, Tricamo E, Markowitz J, Klein DF. 1989. Phenelzine and imipramine in mood reactive depressives: further delineation of the syndrome of atypical depression. Arch Gen Psychiatry 46:787-93.
26. Quitkin FM, Stewart JS, McGrath PJ, Liebowitz MR, Harrison WM, Tricamo E, Klein DF, Rabkin JG, Markowitz JS, Wager SG. 1988. Phenelzine versus imipramine in the treatment of probable atypical depression: defining syndrome boundaries of selective MAOI responders. Am J Psychiatry 145:306-11.
27. Robinson DS, Lerfald SC, Bennett B, Laux D, Devereaux E, Kayser A, Corcella J, Albright D. 1991. Continuation and maintenance treatment of major depression with the monamine oxidase inhibitor phenelzine: a double-blind placebo-controlled discontinuation study. Psychopharmacol Bull 27:31-9.
28. Roth M, Guelfi J-D. 1992. The efficacy of reversible monoamine oxidase inhibitors in depressive illness. Can J Psychiatry 37(1 Suppl):18S-24S.
29. Shulman KI, Walker SE, McKenzie S, Knowles S. 1989. Dietary restriction, tyramine and the use of monoamine oxidase inhibitors. J Clin Psychopharmacol 9:397-402.
30. Tyrer P. 1984. Clinical effects of abrupt withdrawal from tricyclic antidepressants and monoamine oxidase inhibitors after long-term treatment. J Affect Disord 6:1-7.
31. UK Moclobemide Study Group. 1994. A multicentre comparative trial of moclobemide, imipramine and placebo in major depressive disorder. Int Clin Psychopharmacol 9:109-13.
32. Versiani M, Nardi AE, Mundim FD, Alves AB, Liebowitz MR, Amrein R. 1992. Pharmacotherapy of social phobia: a controlled study with moclobemide and phenelzine. Br J Psychiatry 161:353-60.
33. Williams R, Edwards RA, Newbum GM, Mullen R, Menkes DB, Seglar C. 1993. A double-blind comparison of moclobemide and fluoxetine in the treatment of depressive disorders. Int Clin Psychopharmacol 7:155-8.
34. World Health Organization Mental Health Collaborating Centres. 1989. Pharmacotherapy of depressive disorders. J Affect Disord 17:197-8.